Jake R. Morgan, PhD
Research Assistant Professor
Boston University School of Public Health
Dept of Health Law, Policy & Management

PhD, Boston University
MS, Montana State University




Jake Morgan, PhD, is a health services researcher specializing in using real-world data to inform evidence-based policy, update clinical guidelines, and improve patient access to and quality of care.

His work is focused on the opioid overdose epidemic and how to best support patients by promoting access and retention to medications for opioid use disorder. His work on the comparative effectiveness of medications for opioid use disorder has been cited in a call for research by the director of the National Institute on Drug Abuse Nora Volkow and he has a history of collaboration with Massachusetts Department of Public Health to evaluate and inform addiction treatment services. His work has consistently reinforced the importance of patient choice when it comes to treatment for opioid use disorder and has documented the effects of policies that usurp this choice through onerous requirements for treatment, restricting access to vulnerable populations such as individuals who are incarcerated, and cost-sharing schemes that disincentivize treatment. As an applied health economist with extensive experience in statistical, econometric, and simulation modeling approaches, Dr. Morgan frequently works alongside clinical researchers to highlight (and cost) the best treatment interventions for patients. He is currently involved with the Health Economics core of the The HEALing Communities Study; the Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND) study; the Researching Effective Strategies to Prevent Opioid Death (RESPOND) simulation model, and; The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for HCV trial.

Dr. Morgan works closely with The Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) as a member of the Population Data and Modeling Core and is the primary representative for Boston University School of Public Health. The Center’s mission is to develop and disseminate health economic research on healthcare utilization, health outcomes, and health-related behaviors to inform policy to improve care for individuals with substance use disorder, HIV, and HCV. To that end, CHERISH offers resources and consultations to support this type of research for trainees and investigators at any stage. Please see https://cherishresearch.org/ or contact Dr. Morgan to learn more.

2016 Patient-Centered Outcomes Research Institute (PCORI): Trainee Scholarship
2015 Lee Lusted Prize winner


The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for HCV Trial
01/01/2019 - 12/31/2022 (Subcontract PI)
Denver Health Medical Center NIH NIDA
5R01DA042982-03

Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND)
05/15/2019 - 02/28/2022 (Subcontract PI)
Weill Medical College of Cornell NIH NIDA
5U01DA047408-03

IMPROVING NALOXONE ACCESS AND ITS EFFECTS ON DRUG ABUSE AND OVERDOSES
02/25/2019 - 09/29/2021 (Subcontract PI)
RAND Corporation HHS CDC
5R01CE002999-02

Expanding FDA's Opioids Systems Model to Enable Economic Evaluations and Outcome Analyses of National Opioid Policies
09/01/2020 - 08/31/2021 (Subcontract PI)
General Hospital Corp d/b/a Massachusetts General Hospital HHS FDA
1U01FD007064-01

CFAR Developmental Award: Assessing Trends in HIV PrEP Uptake Among Persons Who Inject Drugs
07/01/2020 - 06/30/2021 (Subcontract PI)
Boston Medical Center Corporation NIH NIAID
5P30AI042853-22

Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Evaluating Intervention Outcomes for Individuals, Systems, and Communities
07/15/2020 - 04/30/2021 (Subcontract PI)
Weill Medical College of Cornell University NIH NIDA
2P30DA040500-06A1

Impact of health insurance type and transitions on treatment for opioid use disorder
04/01/2019 - 03/31/2021 (Subcontract PI)
Boston Medical Center Corporation Robert Wood Johnson


Researching Effective Strategies to Prevent Opioid Death (RESPOND)
04/01/2019 - 03/31/2021 (Subcontract PI)
Boston Medical Center Corporation NIH NIDA
5R01DA046527-03

Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care (CHERISH Supplement)
05/01/2019 - 07/15/2020 (Subcontract PI)
Weill Medical College of Cornell NIH NIDA
3P30DA040500-05S1

WHO Level of Detection
04/01/2019 - 06/30/2020 (Subcontract PI)
FIND Foundation World Health Org


Showing 10 of 11 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Zang X, Macmadu A, Krieger MS, Behrends CN, Green TC, Morgan JR, Murphy SM, Nolen S, Walley AY, Schackman BR, Marshall BD. Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. Int J Drug Policy. 2021 Sep 02; 98:103435.View Related Profiles. PMID: 34482264
     
  2. Morgan JR, Quinn EK, Chaisson CE, Ciemins E, Stempniewicz N, White LF, Larochelle MR. Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder. J Subst Abuse Treat. 2021 Jun 17; 108540.View Related Profiles. PMID: 34148756
     
  3. Mills JM, Morgan JR, Dhaliwal A, Perkins RB. Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort. Gynecol Oncol. 2021 Aug; 162(2):308-314.View Related Profiles. PMID: 34090706
     
  4. Morgan JR, Walley AY, Murphy SM, Chatterjee A, Hadland SE, Barocas J, Linas BP, Assoumou SA. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug Alcohol Depend. 2021 08 01; 225:108764.View Related Profiles. PMID: 34051547
     
  5. Hadland SE, Bagley SM, Gai MJ, Earlywine JJ, Schoenberger SF, Morgan JR, Barocas JA. Opioid use disorder and overdose among youth following an initial opioid prescription. Addiction. 2021 10; 116(10):2790-2800.View Related Profiles. PMID: 33739476
     
  6. Morgan JR, Savinkina A, Pires Dos Santos AG, Xue Z, Shilton S, Linas B. HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients. Adv Ther. 2021 03; 38(3):1690-1700.View Related Profiles. PMID: 33590445; PMCID: PMC7932931; DOI: 10.1007/s12325-021-01647-4;
     
  7. Linas BP, Savinkina A, Madushani RWMA, Wang J, Eftekhari Yazdi G, Chatterjee A, Walley AY, Morgan JR, Epstein RL, Assoumou SA, Murphy SM, Schackman BR, Chrysanthopoulou SA, White LF, Barocas JA. Projected Estimates of Opioid Mortality After Community-Level Interventions. JAMA Netw Open. 2021 02 01; 4(2):e2037259.View Related Profiles. PMID: 33587136; PMCID: PMC7885041; DOI: 10.1001/jamanetworkopen.2020.37259;
     
  8. Barocas JA, Morgan JR, Wang J, McLoone D, Wurcel A, Stein MD. Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis. Clin Infect Dis. 2021 02 01; 72(3):472-478.View Related Profiles. PMID: 31960025; PMCID: PMC7850516; DOI: 10.1093/cid/ciaa062;
     
  9. Morgan JR, Barocas JA, Murphy SM, Epstein RL, Stein MD, Schackman BR, Walley AY, Linas BP. Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. JAMA Netw Open. 2020 12 01; 3(12):e2029676.View Related Profiles. PMID: 33320266; PMCID: PMC7739119; DOI: 10.1001/jamanetworkopen.2020.29676;
     
  10. Bronico JVR, Matthews BJ, Perkins RB, Lee EM, Morgan JR, Nitschmann CC, Paasche-Orlow MK. Incidence of Gynecologic Cancers in Women after Uterine Artery Embolization. J Minim Invasive Gynecol. 2021 06; 28(6):1231-1236.View Related Profiles. PMID: 33115685
     
Showing 10 of 39 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 39 publications over 8 distinct years, with a maximum of 8 publications in 2021

YearPublications
20141
20156
20164
20173
20185
20196
20206
20218
Contact for Mentoring:
Morgan's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department